Amelia B. Zelnak, MD, MSc | Authors

K MART PHCY

1501 US HIGHWAY 1

Articles

Genomic Subtypes in Choosing Adjuvant Therapy for Breast Cancer

March 15, 2013

Additional insight into the biology of ER-positive breast cancers, particularly the higher risk luminal B cancers, could aid in identifying potential targets and new, effective therapies. And though the majority of triple-negative breast cancers are the “basal-like” subtype, significant proportions are in other subtypes.

Clarifying the Role of Neoadjuvant Therapy in Breast Cancer

February 15, 2010

Large clinical trials have demonstrated that preoperative therapy for primary operable breast cancer improves breast-conservation rates, with equivalent disease-free (DFS) and overall survival (OS) compared to adjuvant therapy.[1] Connolly and Stearns provide an excellent review of additional benefits of neoadjuvant therapy and emphasize the importance of a multidisciplinary approach to treating patients in this setting.